Good morning, welcome to the special meeting of the shareholders of Liminal BioSciences Inc. My name is Bruce Pritchard, and I'm the Chief Executive Officer of Liminal. I now call to order the special meeting of the shareholders. I will act as Chairman of the meeting, and I will ask Ms. Marie Iskra, the General Counsel of the company, to act as Secretary of the meeting. We will now start the meeting, and as before, to proactively deal with the changing public health impact of COVID-19 and to mitigate risks to the health and safety of our communities, shareholders, employees, and other stakeholders, this meeting is being held virtually via live audio webcast for the benefit of our shareholders across the world. The business of the meeting will be conducted in English. Questions and comments can be made in both English and French. We will begin by conducting the official business of this meeting. After the official business is completed, we will address any shareholder questions submitted during the meeting. I would now ask our General Counsel, Marie Iskra, to take us through certain procedures for this meeting. Thank you, Mr. Chairman. As this meeting is held virtually via live audio webcast, we think it is necessary to set out a few rules for the orderly conduct of the meeting. Registered shareholders and duly appointed proxy holders who wish to communicate with the members of the management team or wish to present or ask a question in respect of a motion may do so using instant messaging on the Lumi virtual interface. As described in our management proxy circular, duly appointed proxy holders were required to register with our transfer agent and obtain a control number prior to this meeting in order to participate, vote, and ask questions during the meeting. Questions can be submitted by any registered shareholder or duly appointed proxy holder using the instant messaging services of the Lumi virtual interface. When asking a question, please indicate which entity you represent, if any, and confirm that you're a registered shareholder or a duly appointed proxy holder. Questions will only be addressed during the question period at the end of the meeting, provided that questions regarding procedural matters are directly related to the motions before the meeting may be addressed during the meeting. Questions or comments containing inappropriate language or that are otherwise disruptive to the orderly conduct of the meeting for all shareholders will not be addressed. Questions which are already answered or that are redundant or repetitive will not be addressed. For the purposes of the meeting today, voting will be conducted on a single electronic ballot. Registered shareholders and duly appointed proxy holders will be asked to vote on the business item as soon as voting opens or wait until the conclusion of the discussion on each of the resolution prior to casting your votes. I would also like to advise everyone that certain of the comments you will hear today are forward-looking statements that involve assumptions, risks, and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. We refer you to our disclaimer regarding forward-looking statements contained in our Management Discussion and Analysis for the 2021 fiscal year, which is available on SEDAR, EDGAR, and on our website. To expedite the meeting, Mr. Pritchard will move all motions, and no motion will need to be seconded. Please note that only registered holders of common shares of record as of December 5th, 2022, or their duly appointed proxy holders are permitted to participate, ask questions, and vote at this meeting. Thank you, Marie. I will now appoint Computershare Investor Services Inc. as scrutineer. The scrutineer will report on the number of common shares represented in person and by proxy at this meeting and report the voting results. The scrutineer has already provided me with their report on attendance at the meeting, and it shows that quorum has been reached, and I therefore declare the meeting regularly constituted for the transaction of such business as may be properly brought before it. As previously mentioned, for the purposes of the meeting today, voting on all matters will be conducted by a single electronic ballot. You will receive a message on the Lumi virtual interface inviting you to register your votes as soon as the polls are opened. You may cast your vote as soon as the voting opens or wait until the conclusion of the discussion on each resolution prior to casting your vote. The first and only item of business is to consider, and if deemed advisable, to adopt a special resolution, the consolidated resolution, authorizing the Board to amend the articles of the company to effect a consolidation of all the issued and outstanding common shares on the basis of a consolidation ratio of 10 pre-consolidation common shares for one post-consolidation common share, the share consolidation, effective as at the discretion of the Board, provided that the effective date shall be before December 31st, 2023, the effective time. For illustrative purposes, if the share consolidation had been affected as of the date hereof, the number of common shares issued and outstanding would equal approximately 3,104,256 common shares after giving effect to the share consolidation without taking into account the impact of any adjustment required as a result of the treatment of fractional shares. The share consolidation is primarily intended to bring the company into compliance with the requirements for continued listing on Nasdaq, particularly the requirement that the common shares maintain a minimum bid price of $1 per share. As previously disclosed on March 4th, 2022, the company was notified of its non-compliance with minimum bid price requirement. In connection with the previously announced transfer of the trading of the common shares from the Nasdaq Global Market to the Nasdaq Capital Market, Liminal BioSciences was granted a second period of 180 calendar days or until February 27, 2023, to regain compliance with the minimum bid price requirement. If the company does not regain compliance prior to this date, the common shares will be delisted from Nasdaq, but the company will have the option to request a hearing to appeal the delisting determination and request additional time to regain compliance with the minimum bid price requirement. I move that the motion authorizing the Board to amend the articles of the company to affect the consolidation of all the issued and outstanding common shares be ratified and confirmed so w e will now proceed with the voting. As previously mentioned, voting today is conducted by a single electronic ballot. Unless you already cast your votes, please proceed now with voting on today's business item, being the share consolidation. You should already have been prompted to register your votes in respect of the business item. If you have not already done so, please register your votes by accessing the voting page and then pressing on the For or Against button next to the proposal for the share consolidation. Once the electronic balloting closes, the voting page will disappear, and your vote will automatically be submitted. We will now wait a few moments for the completion of the electronic ballots and then move on with the remainder of the meeting. We will provide registered shareholders and duly appointed proxyholders approximately an additional one minute to complete the electronic ballots. Once voting is completed, I would ask that the scrutineer compile the report regarding the results of the voting. We will reconvene in a few moments with the scrutineer's reports and the voting results. Thank you for waiting. I have received the scrutineer's report, and I'm pleased to report that the resolution related to the share consolidation has been carried. This completes the business on the agenda for the special meeting, and I would now like to thank our secretary and our scrutineers for assisting us. Detailed results for each vote will be available shortly on Canadian and U.S. Securities Commission's websites at www.sedar.com and www.sec.gov. Before concluding this meeting, we would be pleased to answer questions from any registered shareholders or duly appointed proxyholder who wishes to address the meeting. For each question we answer, we will summarize the question and read out loud the name of the person who asked such question and, if applicable, the entity such person represents. We'd like to remind you that questions which were already answered or that are redundant or repetitive will not be addressed. At this point, there being no questions, we are now concluding the question and answer portion of this meeting. I declare that this meeting is terminated. Thank you for having taken the time to be with us today.